Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock [Yahoo! Finance]
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference